Format

Send to

Choose Destination
J Matern Fetal Neonatal Med. 2016 Oct;29(19):3234-7. doi: 10.3109/14767058.2015.1121478. Epub 2015 Dec 23.

Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial.

Author information

1
a Department of Pediatrics , Gynecology, Microbiology and Biomedical Sciences, University of Messina , Messina , Italy .
2
b Department of Clinical and Experimental Medicine , University of Messina , Messina , Italy , and.
3
c Obstetric Unit, Mother-Infant Department, University of Modena and Reggio Emilia , Modena , Italy.

Abstract

OBJECTIVE:

To evaluate whether myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) rate in overweight women.

METHODS:

In an open-label, randomized trial, myo-inositol (2 g plus 200 μg folic acid twice a day) or placebo (200 μg folic acid twice a day) was administered from the first trimester to delivery in pregnant overweight non-obese women (pre-pregnancy body mass index ≥ 25 and < 30 kg/m(2)). The primary outcome was the incidence of GDM.

RESULTS:

From January 2012 to December 2014, 220 pregnant women were randomized at two Italian University hospitals, 110 to myo-inositol and 110 to placebo. The incidence of GDM was significantly lower in the myo-inositol group compared to the placebo group (11.6% versus 27.4%, respectively, p = 0.004). Myo-inositol treatment was associated with a 67% risk reduction of developing GDM (OR 0.33; 95% CI 0.15-0.70).

CONCLUSIONS:

Myo-inositol supplementation, administered since early pregnancy, reduces GDM incidence in overweight non-obese women.

KEYWORDS:

Body mass index; gestational diabetes; myo-inositol; obese; overweight

PMID:
26698911
DOI:
10.3109/14767058.2015.1121478
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center